Comparison of the effectiveness of frontline chemoimmunotherapy regimens for follicular lymphoma used in the United States

Leukemia and Lymphoma

Volumn 56, Issue 5, 2015, Pages 1295-1302

  Nastoupil, Loretta J ^a   Sinha, Rajni ^b   Byrtek, Michelle ^c   Ziemiecki, Ryan ^d   Taylor, Michael ^c   Friedberg, Jonathan W ^e   Koff, Jean L ^f   Link, Brian K ^g   Cerhan, James R ^h   Dawson, Keith L ^c   Flowers, Christopher R ^f  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b University Oncology and Hematology Associates   (United States)

^c GENENTECH INC   (United States)

^d RTI HEALTH SOLUTIONS   (United States)

^e UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^f EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^h MAYO CLINIC   (United States)

Author keywords

Chemotherapy; Follicular lymphoma; Frontline; Outcomes; Rituximab

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FLUDARABINE; HEMOGLOBIN; LACTATE DEHYDROGENASE; MITOXANTRONE; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BRAIN CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CLINICAL EFFECTIVENESS; COLON CANCER; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; KIDNEY CANCER; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKEMIA; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYELODYSPLASTIC SYNDROME; OBSERVATIONAL STUDY; PANCREAS CANCER; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; SECOND CANCER; SKIN CANCER; UNITED STATES; UNSPECIFIED SIDE EFFECT; CANCER GRADING; CANCER STAGING; CLINICAL TRIAL; KAPLAN MEIER METHOD; LYMPHOMA, FOLLICULAR; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM METASTASIS; NEOPLASM STAGING; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 84932139921     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2014.953144     Document Type: Article

References (37)

1. Swerdlow SH, Harris NL, Campo E. WHO classif cation of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008. pp 220-226.
2. Anderson JR, Armitage JO, Weisenburger DD. Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes dif er by geographic locations. Non-Hodgkin's Lymphoma Classif cation Project. Ann Oncol 1998;9:717-720.
3. Horning SJ. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 1993;20:75-88.
4. Friedberg JW, Taylor MD, Cerhan JR, et al. Follicular lymphoma in the United States: f rst report of the national Lympho Care study. J Clin Oncol 2009;27:1202-1208.
5. Fisher RI, LeBlanc M, Press OW, et al. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 2005;23:8447-8452.
6. Liu Q, Fayad L, Cabanillas F, et al. Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. J Clin Oncol 2006;24:1582-1589.
7. Sacchi S, Pozzi S, Marcheselli L, et al. Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients. Cancer 2007; 109: 2077-2082.
8. Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as f rst-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013;381:1203-1210.
9. Jacobson CA, Freedman AS. First-line treatment of indolent lymphoma: axing CHOP? Lancet 2013;381:1163-1165.
10. Brice P, Bastion Y, Lepage E, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 1997; 15: 1110-1117.
11. Nastoupil LJ, Sinha R, Byrtek M, et al. The use and Effectiveness of rituximab maintenance in patients with follicular lymphoma diagnosed between 2004 and 2007 in the United States. Cancer 2014; 120:1830-1837.
12. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998;17:2265-2281.
13. Berger ML, Mamdani M, Atkins D, et al. Good research practices for comparative Effectiveness research: def ning, reporting and interpreting nonrandomized studies of treatment Effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report-Part I. Value Health 2009;12:1044-1052.
14. Cox E, Martin BC, Van Staa T, et al. Good research practices for comparative Effectiveness research: approaches to mitigate bias and confounding in the design of nonrandomized studies of treatment Effects using secondary data sources: the International Society for Pharmacoeconomics and Outcomes Research Good Research Practices for Retrospective Database Analysis Task Force Report-Part II. Value Health 2009;12:1053-1061.
15. Johnson ML, Crown W, Martin BC, et al. Good research practices for comparative Effectiveness research: analytic methods to improve causal inference from nonrandomized studies of treatment Effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report-Part III. Value Health 2009;12:1062-1073.
16. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as f rst-line treatment for advanced follicular lymphoma. Blood 2005; 105: 1417-1423.
17. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) signif cantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005; 106: 3725-3732.
18. Zinzani PL, Pulsoni A, Perrotti A, et al. Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. J Clin Oncol 2004;22:2654-2661.
19. Morschhauser F, Seymour J, Feugier P, et al. Impact of induction chemotherapy regimen on response, safety and outcome in the PRIMA study. Ann Oncol 2011; 22(Suppl. 4): Abstract 89.
20. Federico M, Luminari S, Dondi A, et al. R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. J Clin Oncol 2013; 31:1506-1513.
21. Flinn IW, van der Jagt R, Kahl BS, et al. Open-label, randomized, noninferiority study of bendamustine-rituximab or R-CHOP/R-CVP in f rst-line treatment of advanced indolent NHL or MCL: the BRIGHT study. Blood 2014;23:2944-2952.
22. Martin P, Jung S, Johnson J, et al. CALGB 50803 (Alliance): a phase 2 trial of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma. Hematol Oncol 2013; 31(Suppl. 1): Abstract 063.
23. Fowler NH, Neelapu SS, Hagemeister FB, et al. Lenalidomide and rituximab for untreated indolent lymphoma: f nal results of a phase II study. Blood 2012; 120(Suppl 1): Abstract 901.
24. Armitage JO, Carbone PP, Connors JM, et al. Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. J Clin Oncol 2003;21:897-906.
25. McLaughlin P, Estey E, Glassman A, et al. Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with f udarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha. Blood 2005;105:4573-4575.
26. Nastoupil LJ, Neelapu SS, Samaniego F, et al. 10-year remission rates following rituximab (R) and FND chemotherapy (f udarabine, mitoxantrone, dexamethasone) with interferon (IFN) maintenance in indolent lymphoma: results of a randomized study. J Clin Oncol 2014; 32(Suppl. 1): Abstract 8528.
27. Al-Tourah AJ, Gill KK, Chhanabhai M, et al. Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma. J Clin Oncol 2008;26:5165-5169.
28. Link BK, Maurer MJ, Nowakowski GS, et al. Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/Mayo Clinic Specialized Program of Research Excellence Molecular Epidemiology Resource. J Clin Oncol 2013;31:3272-3278.
29. Wagner-Johnston N, Link BK, Taylor M, et al. Risk factors for early transformation of follicular lymphoma: report from the National LymphoCare Study. Blood 2009; 114(Suppl. 1): Abstract 2698.
30. Kimby E, Björkholm M, Gahrton G, et al. Chlorambucil/prednisone vs. CHOP in symptomatic low-grade non-Hodgkin's lymphomas: a randomized trial from the Lymphoma Group of Central Sweden. Ann Oncol 1994; 5(Suppl. 2): S67-S71.
31. Paus R, Haslam IS, Sharov AA, et al. Pathobiology of chemotherapy-induced hair loss. Lancet Oncol 2013;14:e50-e59.
32. Williams J, Wood C, Cunningham-Warburton P. A narrative study of chemotherapy-induced alopecia. Oncol Nurs Forum 1999; 26: 1463-1468.
33. Richer MC, Ezer H. Living in it, living with it, and moving on: dimensions of meaning during chemotherapy. Oncol Nurs Forum 2002;29:113-119.
34. Kissane DW, Grabsch B, Love A, et al. Psychiatric disorder in women with early stage and advanced breast cancer: a comparative analysis. Aust NZ J Psychiatry 2004; 38: 320-326.
35. Luoma ML, Hakamies-Blomqvist L. The meaning of quality of life in patients being treated for advanced breast cancer: a qualitative study. Psychooncology 2004;13:729-739.
36. Freedman TG. Social and cultural dimensions of hair loss in women treated for breast cancer. Cancer Nurs 1994;17:334-341.
37. McGarvey EL, Baum LD, Pinkerton RC, et al. Psychological sequelae and alopecia among women with cancer. Cancer Pract 2001;9:283-289.